AmSurg, SCA, USPI & More – 6 Recent Key Notes on ASC Companies
AmSurg completed the first quarter of 2014 with seven letters of intent and one de novo center under development. Net earnings from continuing operations attributable to AmSurg common shareholders were $0.55 per diluted share, or $17.5 million, compared to $0.56 per diluted share, or $17.8 million, in the first quarter of 2013.
Hospital Corporation of America reaffirmed its guidance ranges for 2014, which included revenue of $35.5 billion and adjusted EBITDA of $6.6 billion on the low ends. As of March 31, HCA operated 115 ambulatory surgery centers.
Surgical Care Affiliates reported $217.5 million in total net operating revenues for the fourth quarter of 2013, up 10.1 percent from $197.6 million. As of Dec. 31, 2013, SCA operated 177 surgical facilities.
Barbara Pulliam, BS, CASC, has joined Surgical Management Professionals as vice president of revenue cycle.
Tenet Healthcare Corp. shares were at $45.41 during the week of April 28 to May 2.
United Surgical Partners International reported consolidated net revenues of $145.3 million for the first quarter of 2014, compared to $145.1 million during the same period in 2013. The company acquired two facilities in the first quarter.
If you have a question, issue or note to suggest on an ASC management and development company please contact Carrie Pallardy at firstname.lastname@example.org or Laura Miller at email@example.com.
More Articles on ASC Issues:
Florida Bill Proposing 3-Day ASC Stays Dies in House
Outpatient Overload: Achieve ASC Success in Saturated Markets From ASCOA's Luke Lambert
5 Statistics on ASC Company Fee Rates
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- This peptide may treat bacterial infections: 3 study insights
- Crohn's & Colitis Foundation shares results from IBD Qorus pilot program: 3 notes
- Patients over 75 years old may not benefit from colonoscopy: 4 study insights
- FDA approves Janssen Biotech's STELARA; Boston Scientific leads GI/endoscopic device market & more: 7 GI company key notes
- Outpatient hip resurfacing lowers cost up to 60%: 5 study insights